Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Feb 27, 2023; 15(2): 222-233
Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.222
Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.222
Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies
Ying-Jie Li, Xin-Zhi Liu, Nan Chen, Ai-Wen Wu, Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Yun-Feng Yao, Gastro-intestinal Ward III, Beijing Cancer Hospital, Beijing 100142, China
Zhong-Wu Li, Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
Xiao-Yan Zhang, Department of Radiology, Peking University Cancer Hospital & Institute, Beijing 100142, China
Xin-Feng Lin, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China
Author contributions: Wu AW contributed to conception and design of the study, draft and final approval of the manuscript; Li YJ contributed to collection of the data, draft the manuscript, study design and statistical analysis; Wu AW, Li YJ, Liu XZ and Yao YF, Li ZW, Zhang XY, Lin XF contributed to quality control of the study especially the surgery part, acquisition of data; All authors approved the final manuscript.
Supported by the National Natural Science Foundation of China , No. 82173156 ; Beijing Hospitals Authority Clinical Medicine Development of Special Funding , No. ZYLX202116 .
Institutional review board statement: This study was approved by the ethics committee of Peking University cancer hospital (approval no. 2022YJZ39).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at drwuaw@sina.com.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ai-Wen Wu, MD, PhD, Academic Editor, Director, Doctor, Professor, Surgeon, Teacher, Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. drwuaw@sina.com
Received: November 29, 2022
Peer-review started: November 29, 2022
First decision: December 27, 2022
Revised: January 8, 2023
Accepted: February 1, 2023
Article in press: February 1, 2023
Published online: February 27, 2023
Processing time: 90 Days and 3.1 Hours
Peer-review started: November 29, 2022
First decision: December 27, 2022
Revised: January 8, 2023
Accepted: February 1, 2023
Article in press: February 1, 2023
Published online: February 27, 2023
Processing time: 90 Days and 3.1 Hours
Core Tip
Core Tip: To the best of our knowledge, this retrospective study is one of the few to summarize mismatch repair-deficient/microsatellite instability-high gastric, duodenal, and colorectal cancers for preoperative immunotherapy. The cohort was a sequential case analysis that only one patient was excluded from the cohort because symptoms disappeared after programmed death protein 1 therapy and she refused to examination and further treatment.